肌成纤维细胞对矽肺发病及治疗的研究进展  

Research progress of myofibroblast in pathogenesis and treatment of silicosis

作　　者：刘贵钱 张晓华 李颖 LIU Gui-qian;ZHANG Xiao-hua;LI Ying(Department of Occupational Diseases,Hunan Prevention and Treatment Institute Occupational Medicine,Changsha Hunan,410007,China)

机构地区：[1]湖南省职业病防治院职业病科,湖南长沙410007

出　　处：《职业与健康》2020年第17期2445-2448,共4页Occupation and Health

基　　金：湖南省自然科学基金(2017JJ3184)。

摘　　要：矽肺是尘肺病的一种,也是我国危害最严重和最常见的职业病。目前,矽肺发病机制尚未完全明确,尚无一个特效的治疗方法和特效药物来逆转肺纤维化。近年来研究表明,肌成纤维细胞是矽肺病肺纤维化过程中发挥关键效应的细胞。文章就肌成纤维细胞对矽肺病发病机制及治疗的研究进展进行综述,为探索矽肺病发病的分子机制以延缓或阻断纤维化进程提供帮助。The silicosis is a kind of pneumoconiosis,which is the most serious harm and the most common occupational disease in China.At present,the pathogenesis of silicosis has not been fully identified,and there is no specific treatment or drug to reverse pulmonary fibrosis.Recent studies have shown that myofibroblasts are the key effector cells in the process of silicosis pulmonary fibrosis.This paper reviews the progress of myofibroblast in the pathogenesis and treatment of silicosis,in order to explore the molecular mechanism of silicosis to delay or block the process of fibrosis.

关 键 词：矽肺 肌成纤维细胞 发病机制 治疗 

分 类 号：R135.2[医药卫生—劳动卫生]